相关实验视频

Updated: Jun 11, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

周围血液免疫类型的动态变化及其在接受免疫检查点阻塞治疗的宫癌患者的预后价值

Wenjian Gong¹, Zhi Wang², Yongqiang Wei³

¹National Clinical Research Center for Obstetrics and Gynecology, Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Discover oncology

|February 12, 2025

概括

免疫检查点阻塞 (ICB) 疗法在晚期宫癌 (CC) 中表现有前途. 周围血液免疫细胞的变化,如抑制T细胞的增加,与整体存活 (OS) 相相关,表明潜在的预后生物标志物.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
翻译医学是一种翻译医学.

背景情况:

免疫检查点阻塞 (ICB) 治疗,特别是针对编程细胞死亡-1 (PD-1) 途径,改善了晚期宫癌 (CC) 的存活率.
虽然ICB会影响周围血液中的免疫细胞和成分,但动态变化及其与整体存活率 (OS) 的关联在CC患者中仍未得到充分研究.

研究的目的:

为了研究晚期CC患者在ICB治疗期间外周血液免疫类型的动态变化.
分析基线和治疗后的外周血液免疫标志物和接受ICB的CC患者的OS之间的关联.

主要方法:

在2019年12月至2022年9月期间接受ICB治疗的119名晚期CC患者的回顾性分析.
边缘血液免疫细胞,免疫球蛋白和补充成分的动态变化在基线和第二次ICB周期后被评估.
多变量考克斯回归分析被用来确定外周血液标记物和OS之间的关联.

主要成果:

在ICB后,抑制T (Ts) 细胞和自然杀手细胞 (NK) 显著增加,Th/Ts比率和IgM水平下降.
细胞毒性T (Tc) 细胞,T细胞,Th/Ts比,以及IgM,IgA,C3和C4水平的百分比与患者的生存状况有关.
高的IgA水平与糟糕的生存状况显著相关 (HR=2.918,P=0.035).

结论:

在一些CC患者中,ICB疗法可能会诱导外周抗瘤T细胞的增殖.
周围血液免疫类型标志物显示出潜在的预后工具,用于预测ICB接受的晚期CC患者的OS.

关键词:

抗PD-1病毒的使用.宫癌是发生在宫癌的原因之一.在 IgA A 里面.周围血液周围血液细胞 Ts 细胞 Ts 细胞

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.